Effect of Majun E Seer Alvi Khani on increased lipid levels across different Temperaments

To Evaluate the Efficacy of Majun E Seer Alvi Khani On Fart E Tadassum Fid Dam Hyperlipidaemia Across Bilious and Phlegmatic Temperaments - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/11/076195

Enrollment

Registered

2024-11-04

Start date

Unknown

Completion date

Unknown

Last updated

2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E785- Hyperlipidemia, unspecified

Interventions

Intervention1: Majun E Seer Alvi Khani: 7 Grams Once a day after breakfast for the duration of 40 days. Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: Patients of both gender Patients who have not started hypolipidaemic agents yet Mild to moderate ranges of different lipids in lipid profile

Exclusion criteria

Exclusion criteria: Pregnant and lactating females Uncontrolled hypertension Patients of chronic heart disease Diabetic patients Patients of chronic kidney disease Inflammatory bowel syndrome and peptic ulcers Tuberculosis Patients having any malignancy

Design outcomes

Primary

Measure	Time frame
Reduction in serum lipid levels in participants after 40 days of treatment with Majun E Seer Alvi Khani. Changes in lipid profiles will be measured from baseline to post-intervention to determine the efficacy of the formulation in managing hyperlipidaemia. Timepoint: 1. BASELINE(day 0) Collect demographic data, medical history and baseline temperamental assessment (bilious and phlegmatic) Perform initial Lipid {Profile test 2. Day 40 End of treatment Perform final lipid profile test to evaluate the efficacy of the treatment. Assess Overall Wellbeing	—

Measure

Time frame

Reduction in serum lipid levels in participants after 40 days of treatment with Majun E Seer Alvi Khani. Changes in lipid profiles will be measured from baseline to post-intervention to determine the efficacy of the formulation in managing hyperlipidaemia. Timepoint: 1. BASELINE(day 0) Collect demographic data, medical history and baseline temperamental assessment (bilious and phlegmatic) Perform initial Lipid {Profile test 2. Day 40 End of treatment Perform final lipid profile test to evaluate the efficacy of the treatment. Assess Overall Wellbeing

—

Secondary

Measure	Time frame
1. The effect of Majun E Seer Alvi Khani on participants’ overall well-being. 2. Any changes in body weight and BMI. 3. The incidence of any adverse effects during the course of the treatment.Timepoint: 1. BASELINE(day 0) Collect demographic data, medical history and baseline temperamental assessment (bilious and phlegmatic) Perform initial Lipid {Profile test 2. Day 40 End of treatment Perform final lipid profile test to evaluate the efficacy of the treatment. Assess Overall Wellbeing	—

Measure

Time frame

1. The effect of Majun E Seer Alvi Khani on participants’ overall well-being. 2. Any changes in body weight and BMI. 3. The incidence of any adverse effects during the course of the treatment.Timepoint: 1. BASELINE(day 0) Collect demographic data, medical history and baseline temperamental assessment (bilious and phlegmatic) Perform initial Lipid {Profile test 2. Day 40 End of treatment Perform final lipid profile test to evaluate the efficacy of the treatment. Assess Overall Wellbeing

—

Countries

India

Contacts

Public ContactDr Afreen Begum

Govt Nizamia Tibbi College and General Hospital

yousufmohd96@gmail.com9912904786

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026